Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Midatech Appoints Dr Jim Phillips as Chief Executive Officer

Published: Wednesday, October 02, 2013
Last Updated: Wednesday, October 02, 2013
Bookmark and Share
Dr Philips has over 25 years of senior management and Board level experience in public and private companies across Europe, the US and Australia.

During this time he has accumulated considerable expertise in M&A and licensing deal origination and execution, which he now brings to the role of CEO of Midatech.

Dr Phillips joins Midatech from Healthcare Brands International Ltd (HBI), the UK consumer healthcare company, where he has been CEO since 2010. Between 2007 and 2012 he served as Non-executive Chairman of Prosonix Ltd, a specialty pharmaceutical company developing respiratory medicines using an innovative particle-engineering technology and approach.

Before joining HBI, Dr Phillips was CEO of Vantia Ltd., a pharmaceutical company developing novel, small molecule drugs. Prior to that he founded and served as CEO of Talisker Pharma until its acquisition by EUSA in 2006, upon which he became President of EUSA Pharma Europe and an Executive Board Member EUSA Pharma Inc. Dr Phillips has also held senior roles in drug and business development in Novartis and Johnson & Johnson.

Commenting on the appointment, Professor Thomas Rademacher, Chairman of Midatech said: “I am very pleased to welcome Jim to the Company as our new CEO. I have no doubt his senior management and commercial experience within the Biotechnology sector will help us sign the partnership deals and raise the funds we need to deliver the significant potential of our unique gold-nanoparticle technology.”

Dr Philips added: “I am excited to have joined Midatech at this crucial stage as it accelerates the development and commercialisation of its novel gold nanoparticle technology. With its potential to greatly improve the delivery of important drugs for the treatment of diabetes and various cancer types, as well as uses in medical diagnostics and imaging, I am confident that Midatech will generate significant growth and value over the next several years.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Midatech Announces the Opening of cGMP Standard Facility
Midatech Biogune S.L. is said to be the world’s first cGMP grade manufacturing plant for the production of nanoparticles at a scale commensurate with pharmaceutical applications.
Monday, May 07, 2007
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!